News & analysis on the clinical development and manufacture of large molecule drugs
News from Theorem and Symbiosis – People on the move
By Dan Stanton
- Last updated on
First up, news from Theorem Clinical Research and with more than 25 years of biopharmaceutical experience Connie Wierman has been named VP of Biopharmaceutical Development.
Before joining Theorem Wierman held a number of executive posts including VP of clinical development in oncology for INC Research.
Theorem President and CEO John Potthoff said: “She has built an impressive career with an emphasis on the global clinical development of oncology therapies. We count on her to provide an excellent operational environment and successful outcomes for our clients.”
Ponthoff also recently spoke to Outsourcing-Pharma.com regarding the recently held Avoca Quality Consortium Summit. Read them here.
Next we have news from Symbiosis Pharmaceutical Services, a small-scale contract manufacturer of novel injectable pharmaceuticals for use in clinical trials, who has appointed Joanne Anderson as its new Business Development Manager.
Anderson, with over 12 years of experience in the pharma industry, comes from a background of Programme Management and has previously been responsible for an R&D portfolio of new product developments.
“We are delighted to have Joanne joining the Symbiosis team,” said Symbiosis CEO Colin Mackay. “Joanne’s energy and experience aligns with the ambitions of the company and strengthens our ability to tailor our services to our clients’ specific sterile manufacturing needs and not the other way around!”
And click here to read about Symbiosis’s recent hunt for US clients wanting to run trials in Europe.
Oncology services company Biologics has announced the addition of Jenny Niedling to its Regional Oncology Liaison team.
Niedling, who has spent the last eight years with Bristol Myers-Squibb, will be supporting oncology providers in the Southern US territories.
Paula Bickley, VP of Physician Services said: “Her experience coupled with her dedication and drive to help support the cancer community will have an immediate impact on helping our team achieve its goals.”
And finally this week, John Castellani, the President and CEO of the PhRMA (Pharmaceutical Research and Manufacturers of America) has been appointed to the Pharmacist Partners' Advisory Board.
He said: “I am proud to join the Advisory Board of Pharmacist Partners to help advance our shared objectives of improving medication literacy and adherence to medicines – all of which are focused on helping patients enjoy healthier lives. Improving patient health requires constructive and informed engagement among all stakeholders in the health care delivery chain, including pharmacists, prescribers and biopharmaceutical research companies.”